SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
System improves management for people with diabetes by offering finger prick-free monitoring System improves management for people with diabetes by offering finger prick-free monitoring Dexcom – ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo as ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
The simple and easy to use Dexcom ONE rt-CGM system is now listed on the NHS England, Wales, Scotland and Northern Ireland drug tariffs The first of Dexcom's scan-free and finger prick-free devices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback